Related Experiment Video
Updated: Jan 12, 2026
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Memantine modulates neuroinflammation and motor coordination in a Parkinson's disease model
Hyunha Choi1, Su Bin Hwang1, Hye Yeon Cho1
1Data Convergence Drug Research Center, Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, South Korea; College of Pharmacy, Chungnam National University, Daejeon, South Korea.
Abstract:
Memantine, an NMDA receptor antagonist clinically approved for Alzheimer's disease, has been implicated in modulating neuroinflammatory responses beyond its anti-excitotoxic actions. To explore its potential relevance in Parkinson's disease, this study evaluated memantine's effects in both LPS-activated microglial cells and a synucleinopathy mouse model. In BV-2 cells, memantine elicited a modest but measurable attenuation of TNF-α and IL-6 secretion, which was accompanied by downregulation of TLR4 and IκB signaling. In vivo, 5-month oral administration of memantine to mThy1-αSyn transgenic mice led to moderate improvements in motor function as assessed by beam-walk performance. Immunohistochemical analyses revealed decreased microglial activation in the cerebral cortex; however, phosphorylated α-synuclein accumulation and tyrosine hydroxylase expression remained unaffected. Furthermore, spatial working memory was not improved by treatment. Taken together, these findings suggest that memantine may exert beneficial effects on neuroinflammatory processes and behavioral deficits in PD-relevant models. However, its impact on the hallmark neuropathology of PD appears limited.
Insights
Memantine shows potential in Parkinson's disease (PD) models by reducing neuroinflammation and improving motor function. However, it did not affect key PD pathologies like alpha-synuclein accumulation.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Memantine, an NMDA receptor antagonist for Alzheimer's disease, may influence neuroinflammation.
- Its potential therapeutic role in Parkinson's disease (PD) warrants investigation.
Purpose of the Study:
- To evaluate memantine's effects on neuroinflammation and motor deficits in PD models.
- To assess its impact on microglial activation and alpha-synuclein pathology.
Main Methods:
- In vitro: LPS-activated BV-2 microglial cells treated with memantine.
- In vivo: mThy1-αSyn transgenic mice administered memantine orally for 5 months.
- Behavioral tests (beam-walk) and immunohistochemical analyses were performed.
Main Results:
- Memantine reduced TNF-α and IL-6 secretion in microglial cells, downregulating TLR4 and IκB signaling.
- Oral memantine improved motor function in mice, correlating with decreased microglial activation.
- No significant changes were observed in phosphorylated alpha-synuclein or tyrosine hydroxylase levels.
Conclusions:
- Memantine demonstrates neuroprotective potential by modulating inflammatory responses and improving motor deficits in PD models.
- Its efficacy against core PD neuropathology, such as alpha-synuclein aggregation, appears limited.
- Further research is needed to clarify memantine's role in PD treatment
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:15Parkinson's Disease: Overview
01:37Neural Regulation
01:22Alzheimer's Disease: Treatment
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists